BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:49 PM
 | 
May 21, 2010
 |  BC Extra  |  Clinical News

Ipilimumab meets NSCLC endpoint

Bristol-Myers Squibb Co. (NYSE:BMY) said both regimens of 10 mg/kg ipilimumab every three weeks in combination with chemotherapy met the primary endpoint vs. chemotherapy alone in the Phase II...

Read the full 128 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >